Trial Profile
Bortezomib subcutaneous versus intravenous: analysis of the incidence of bortezomib-induced peripheral neuropathy in Korean patients with multiple myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Oct 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 15 Oct 2015 New trial record
- 06 Aug 2014 Results published in the journal of Cancer Chemotherapy and Pharmacology.